Selection of Peptide Receptors Coexpressed in Specific Cancer Types
| Cancer type | Peptide receptor | Incidence in cancer | References |
| NETs | |||
| Ileal | Somatostatin (sst2 > sst3 > sst5 or sst1) | sst2 > 90% | 4,7 |
| CCK2 | 60% | 7,12 | |
| GIP | 86% | 10,14 | |
| GLP-1 | 30% | 7,8,14 | |
| Glucagon | 35% | ||
| Insulinomas | GLP-1 | >90% | 7,8,14 |
| GIP | 100% | 10,14 | |
| Glucagon | >90% | ||
| Somatostatin (sst1, sst5, sst2) | 70% | 4,7 | |
| MTC | CCK2 | >90% | 12 |
| GIP | 89% | 15 | |
| Somatostatin (sst2) | 100% (antagonist†) | 25 | |
| Non-NETs | |||
| Prostate cancer | GRP | >90% | 16,17 |
| PSMA* | >90% | 18 | |
| Breast cancer | GRP | 65%–75% | 20,23 |
| NPY (Y1 subtype) | 66%–85% | 22 | |
| Somatostatin (sst2) | >90% (antagonist†) | 23–25 | |
| GIST | GRP | 84% | 26 |
| CCK2 | 63% | 26 | |
| VPAC2 | 84% | 26 | |
| Ewing sarcoma | Neurotensin (NT1 subtype) | 64% | 27 |
| NPY (Y1 subtype) | 84% | 28 | |
| Glioblastoma | Substance P (NK1) | 100% | 29 |
| NPY (Y2 subtype) | 83% | 30 |